Sign in Subscribe
Mental health

Glutamatergic Dysfunction in Schizophrenia Revealed Through New Research

Strategic Insights

— 1 min read

Researchers have made a significant discovery in understanding the mental health condition of psychosis, specifically focusing on schizophrenia. A recent study published in Molecular Psychiatry found that glutamatergic dysfunction is a key factor in this condition. The study involved measuring glutamate levels in the brains of patients with first-episode psychosis and healthy controls, and the results showed a correlation between glutamate levels and symptoms of attention.

The researchers used linear mixed models to analyze the data, and the results indicated that glutamate levels in the dorsal anterior cingulate cortex (dACC) were lower in patients with first-episode psychosis compared to healthy controls. This difference was associated with deficits in attention at all visits. The study also found that glutamatergic compounds that decrease thalamic and increase dACC glutamate levels may be beneficial in first-episode psychosis over the first two years of illness.

Key Takeaways:

  • The study found that glutamatergic dysfunction is associated with schizophrenia, and glutamatergic compounds may be beneficial in treating the condition.
  • Glutamate levels in the dACC were lower in patients with first-episode psychosis compared to healthy controls.
  • The difference in glutamate levels was associated with deficits in attention at all visits.
  • The study involved 57 patients with first-episode psychosis and 55 healthy controls.
  • The research was funded by Ph.D. grants from the Faculty of Health and Medical Sciences, University of Copenhagen, and other organizations.
  • The study's findings have significant implications for the development of new treatments for schizophrenia.

Statistics:

  • 57 patients with first-episode psychosis participated in the study.
  • 55 healthy controls participated in the study.
  • The study found a significant difference in glutamate levels between patients with first-episode psychosis and healthy controls (p = 0.03).
  • Patients with first-episode psychosis had deficits in attention at all visits (p < 0.05).
  • The study involved multiple visits over a two-year period, including baseline, six weeks, six months, and two years.

Sources:

  • NewsRx. Investigators from Copenhagen University Hospital Release New Data on Psychosis (Cerebral Glutamate Levels Over Two Years In Initially Antipsychotic-naive First-episode Patients With Psychosis Are Related To Clinical Symptoms and Cognition). Mental Health Weekly Digest. October 13, 2025; p 400.
  • Cerebral Glutamate Levels Over Two Years In Initially Antipsychotic-naive First-episode Patients With Psychosis Are Related To Clinical Symptoms and Cognition. Molecular Psychiatry, 2025.
  • University of Copenhagen Faculty of Health and Medical Sciences. Ph.D. grants.

Read more